Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study
Maggie Banys‐Paluchowski(University Hospital Schleswig-Holstein), Oreste Gentilini(Dana-Farber Cancer Institute), Michalis Kontos(National and Kapodistrian University of Athens), Geeta Kadayaprath(Max Healthcare), Elmar Stickeler(Universitätsklinikum Aachen), Christine Solbach(Goethe University Frankfurt), Thorsten Kühn(Klinikum Esslingen), Helidon Nina(Mother Teresa Hospital), Jens‐Uwe Blohmer(Sankt Gertrauden Krankenhaus), Laura Niinikoski(University of Helsinki), Petr Krivorotko(Institute of Oncology NN Petrov), Güldeniz Karadeniz Çakmak(Zonguldak Bülent Ecevit University), Isabel T. Rubio(Clinica Universidad de Navarra), David Pinto(Champalimaud Foundation), Michael Hauptmann(Medizinische Hochschule Brandenburg Theodor Fontane), Eduard-Alexandru Bonci(Iuliu Hațieganu University of Medicine and Pharmacy), Maria Luisa Gasparri(University of Bern), Jean‐Marc Classe(Institut de Cancérologie de l'Ouest), Jana de Boniface(Harvard University), Peter Paluchowski(Regio Kliniken), Marc Thill(Agaplesion Markus Hospital), Steffi Hartmann(University of Rostock), Dawid Murawa(University of Zielona Góra), Florentia Peintinger(Medical University of Graz), Lukáš Dostálek(Charles University), Matilda Appelgren(Karolinska Institutet), Zoltán Mátrai(National Institute of Oncology), Rosa Di Micco, Ellen Schlichting(Oslo University Hospital)
Cited by 159
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|2.2k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
|Cancer Discovery|2012|622
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|544